Cointime

Allena Pharmaceuticals

company

About

Allena Pharmaceuticals develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.

  • 101 - 250

Highlights

Total Funding Amount
$78M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$25M
Industries
Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2011
Number Of Employee
101 - 250
Operating Status
Active

Allena Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$78M
Allena Pharmaceuticals has raised a total of $78M in funding over 2 rounds. Their latest funding was raised on Dec 9, 2015 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 9, 2015 Series C $53M 1 — — Detail
Dec 4, 2014 Series B $25M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Allena Pharmaceuticals is funded by 1 investors. Inbio Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Inbio Ventures — Series C
Cointime
เนื้อหา
บริษัท